CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for GLG Pharma SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

GLG Pharma SA
ul. Dunska 9 (Budynek Delta)
Phone: +48 717580979p:+48 717580979 Wroclaw, 54-427  Poland Fax: +48 717503550f:+48 717503550

This company is no longer actively traded on any major stock exchange.

Business Summary
GLG Pharma SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the research and development of therapies based on small molecules and formulations, which inhibit dysfunctional Signal Transducer and Activators of Transcription (STAT3) signaling. STAT3 is a signaling protein, which optimizes the human cell growth. The Company develops projects related to cancer and kidney disease treatment, as well as other drug applications. Its pipeline includes STAT3 inhibitors that mainly aim at treatment of chronic lymphatic leukemia (CLL), polycystic kidney disease (PKD) and triple negative breast cancer (TNBC). The Company performs clinical trials in laboratories located in Poland and the United States.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201912/31/2017Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Supervisory Board IzabelaRoman
Vice Chairman of the Management Board H. R.Gabriel 9/1/2017
Chief Accounting Officer KatarzynaMalarowska
Member of the Supervisory Board Timothy A.Krochuk
Member of the Supervisory Board ManuelWorcel 78

General Information
Outstanding Shares: 8,800,001 (As of 3/31/2019)
Stock Exchange: WAR
Fax Number: +48 717503550


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023